ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Tatiana Galicia-Carmona, Eder Arango-Bravo, Juan Alberto Serrano-Olvera, Celia Flores-de la Torre, Iván Cruz-Esquivel, Ricardo Villalobos-Valencia, Denisse Castro-Eguiluz, Lucely Cetina

Human Vaccines & Immunotherapeutics · 2021 · 24 citations · 25 references

DOIFull text

Open access

Concepts

Abstract

-based vectors infect antigen-presenting cells (APC) and secrete HPV-LLO fusion proteins within the APC cytoplasm, these proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells. ADXS11-001 has demonstrated safety results in phase I-II studies in women with cervical cancer and is being assessed in clinical trials in patients with HPV-positive anal canal and head and neck cancers.

References

25